1. How to submit my research paper? What’s the process of publication of my paper?
The journal receives submitted manuscripts via email only. Please submit your research paper in .doc or.pdf format to the submission email: ijpmbs@ejournal.net.
You’ll be given a paper number if your submission is successful. Your paper then will undergo peer review process, which may take approximately one and a half months under normal circumstances, three tops.
After blind peer review, you will receive the notification letter with the review result of your paper...
2. Can I submit an abstract?
The journal publishes full research papers.[Read More]
 

Biopharmaceutical Innovation on Pharmerging Countries: A Quantitative Analysis and Scenario Prediction

Gabriel G. S. Freire 1, Karina F. Oliveira 1, Igor P. Munhoz 2, and Alessandra C. S. Akkari 1
1.Science and Technology Center of Mackenzie Presbyterian University, Campinas, Brazil
2.Federal Institute of Education, Science and Technology of Sao Paulo, Pirituba Campus, Sao Paulo, Brazil

Abstract—The advancement of biotechnology area has allowed the development of biodrugs and its use implemented for the treatment of complex diseases. Countries with an emerging pharmaceutical market are pointed out as responsible for sustaining the sale growth of new medicines Therefore, a technological and industrial mapping of the biopharmaceutical segment was developed through the analysis of patent data extracted from Derwent and WIPO database. Numerical analyzes were performed, implementing an algorithm in MATLAB, in order to predict scenarios. The importance of Merck and Sartorius, both with about 74 biopharmaceutical patents, stands out. The leading position of U.S. (101,873 patents) and Europe (93,013 patents) has been confirmed, although China has demonstrated a relevant position (36,513 patents) over the twenty years of analysis. Also, Brazil will increasingly attract the interest of different countries in protecting biotechnological products (61.27% increase until 2021) in order to exploit the emerging Brazilian market. The analysis pointed out that pharmerging countries do not stand out among the largest holders of biopharmaceutical patents and presents low exploitation of the opportunities of their emerging markets.
 
Index Terms—biopharmaceutical, innovation, pharmerging country, patents, BRICS

Cite:
Gabriel G. S. Freire, Karina F. Oliveira, Igor P. Munhoz, and Alessandra C. S. Akkari, "Biopharmaceutical Innovation on Pharmerging Countries: A Quantitative Analysis and Scenario Prediction," International Journal of Pharma Medicine and Biological Sciences, Vol. 9, No. 4, pp. 158-163, October 2020. doi: 10.18178/ijpmbs.9.4.158-163

Copyright © 2020 by the authors. This is an open access article distributed under the Creative Commons Attribution License (CC BY-NC-ND 4.0), which permits use, distribution and reproduction in any medium, provided that the article is properly cited, the use is non-commercial and no modifications or adaptations are made.
Copyright © 2012-2024 International Journal of Pharma Medicine and Biological Sciences, All Rights Reserved
E-mail: ijpmbs@ejournal.net